Skip to content

Cancer - starve it out?

Table of contents

Reading time 18 minutes

Aktualisiert – April 13, 2026

Can cancer be starved? No, this is an often misunderstood approach based on the fact that cancer cells have a high glucose turnover.Warburg effect) were present, and the idea arose to simply remove sugar and carbohydrates, thereby „starving“ the cancer.

If one attempts this, one not only suffers from malnutrition, which also has negative effects on healthy cells, but one also motivates the tumor cells to move to more nutrient-rich areas - to metastasize!
So, cancer cells aren't easily outsmarted; they tend to trick us.

However, there are approaches to both slow down the activity of cancer cells and induce them into dormancy, and to strengthen healthy cells and the immune system so that they can keep the tumor in check.

So, the point isn't to destroy or kill the tumor, but to find a healthy balance on which a tolerable coexistence can be established.
In the scientific sense, this corresponds to adaptive or metronomic (chemo)therapy, which has been known for about twenty years but is still not established.

Integrative & Metronomic Oncology

All substances and measures described herein are exclusively adjuvant to be considered conventional therapy. None of them replaces surgical, chemo-, radiation, or immunotherapy treatments.
All measures must be coordinated with the treating oncologists. Interactions with standard therapies are documented below.

Conceptual Foundations – Why „Metronomic“ Instead of „Radical“

The Paradox of Radical Restriction

Radical glucose restriction (zero-carb, extreme ketogenic diet) induces in the tumor via the AMPK signaling pathway a metabolic adaptation. The tumor cells activate:

  • Autophagy
    Self-digestion for energy production, which ensures short-term survival
  • Alternative Substrate
    Glutamine, lactate, acetate, fatty acids (Reverse Warburg effect)
  • Metabolic Phenotype Shift
    Selection of more aggressive, more resistant clone populations
  • HIF-1α upregulation
    under metabolic stress → increased invasiveness

The metronomic principle means instead: continuous, low-dose, multi-target intervention simultaneously across multiple cancer hallmarks (characteristic functional properties acquired by cells during malignant transformation to evade normal growth and surveillance mechanisms and form malignant tumors), without imposing a uniform selective pressure on the tumor.

This approach is analogous to metronomic chemotherapy (low-dose continuous administration instead of high-dose intermittent therapy).

Welche Kliniken bieten metronomische Chemo an?

Aufgeführt sind ausschließlich NICHT-private Kliniken. Der Grund:

Alle deutschen Kliniken mit Kassenzulassung sind gesetzlich zur Veröffentlichung jährlicher Qualitätsberichte verrpflichtet, deren Angaben im Zweifel verlässlicher sind als Marketingaussagen auf Websites privater Praxen oder Kliniken. 

In diesen öffentlichen Berichten lassen sich objektive Daten zur Behandlungsfrequenz (Anzahl der Fälle pro Jahr) und interdisziplinären Zusammenarbeit ermitteln, entscheidende Indikatoren für die Expertise einer Klinik. Außerdem ist für gesetzlich Versicherte der Zugang zu modernen Therapiestandards, wissenschaftlichen Studien and spezialisierten Ambulanzen in diesen Einrichtungen direkt und ohne Zusatzkosten sichergestellt.

  • UKE Hamburg – Universitäres Cancer Center (UCCH)
    II. Medizinische Klinik – Gebäude Ost 43, EG oder O24
    Martinistraße 52 – 20246 Hamburg
    +49 (0) 40 7410-52960
    a.darimont@uke.de
  • Clinicum St. Georg
    Rosenheimer Straße 6-8 – 83043 Bad Aibling
    +49 (0) 80 61-398-0
    info@clinicum-stgeorg.de
  • Universitätsklinikum Regenburg (UKR)
    Franz-Josef-Strauß-Allee 11 – 93053 Regensburg
    +49 (0) 941 944-00941 / +49 (0) 941 944-4488
    info@ukr.de

Nuclear molecular signaling pathways

Warburg Effect & Aerobic Glycolysis

Cancer cells prefer aerobic glycolysis (lactic acid fermentation despite the presence of oxygen). Key molecules:

  • GLUT1/GLUT3 Glucose Transporter
    Overexpressed in most solid tumors
  • HK2 Hexokinase 2
    First rate-limiting step of glycolysis, bound to the outer mitochondrial membrane
  • PKM2 Pyruvate kinase M2
    Fetal Isoform, generates metabolic flexibility
  • LDHA Lactate dehydrogenase A
    Converts pyruvate to lactate, enabling NAD⁺ regeneration
  • HIF-1α Hypoxia-Inducible Factor
    Transkriptionsfaktor, reguliert >200 Gene, fördert Angiogenese, VEGF, Glykolyse

Therapeutic Implication
Not a complete glucose withdrawal, but Modulation of the Glycolysis Signaling Cascade about mTOR inhibition, AMPK activation, and GLUT suppression.

PI3K/Akt/mTOR pathway

The most frequently mutated cascade in human cancers:

Growth Factors (EGF, IGF-1, Insulin)
    ↓
RTK (Receptor Tyrosine Kinase)
    ↓
PI3K → PIP3
    ↓
PDK1/Akt (PKB)
    ↓
mTORC1 ──→ p70S6K, 4E-BP1 → Protein Synthesis, Cell Growth
           ──→ HIF-1α → Angiogenesis
           ──→ GLUT → Glucose Uptake

Activated by:
Hyperinsulinemia
IGF-1 excess
– Mutations in PTEN, PIK3CA, and RAS

AMPK – The Cellular Energy Sensor

AMPK (AMP-activated protein kinase) is the antagonist of mTOR:

  • Activated at increased AMP:ATP ratio (energy deficiency, exercise, metformin, berberine)
  • Phosphorylates TSC2 inhibits Rheb GTPase → mTORC1 inhibition
  • Promotes controlled autophagy (tumor-hostile at a low level)
  • Activated Fatty acid oxidation, reduces lipid synthesis
  • Regulated FOXO3a p21/p27 Expression (Cell Cycle Arrest)

NF-κB and chronic tumor inflammation

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells):

  • Konstitutiv aktiv in >70% aller soliden Tumoren
  • Regulated: IL-6, TNF-α, VEGF, MMP-9, COX-2, Bcl-2, Survivin
  • Promotes: Metastasis, therapy resistance, epithelial-mesenchymal transition (EMT)

STAT3 signaling pathway

STAT3 (Signal Transducer and Activator of Transcription 3):

  • Growth factor receptors (IL-6R, EGFR, HER2) → JAK → STAT3 phosphorylation
  • STAT3-Dimer → Nuclear Import → Transcription of: Cyclin D1, Bcl-xL, VEGF, MMP-2
  • Tumor Microenvironment IL-6 secretion by tumor-associated macrophages activates STAT3 parakrinely

Epigenetics – HDAC & DNMT

Epigenetic Mechanisms of Cancer Development:

HDAC (Histone Deacetylases):

  • Remove acetyl groups from histones → compact chromatin structure → gene silencing
  • Tumor suppressor genes (p21, p16, PTEN) are silenced by HDAC hyperactivity
  • HDAC inhibition → chromatin opening → reactivation of silenced suppressor genes

DNMT (DNA Methyltransferases):

  • Methylation of CpG islands in promoter regions → Gene silencing
  • Tumor suppressors (RARβ, hMLH1, MGMT, CDH1) hypermethylated → inactive
  • DNMT inhibition → demethylation → re-expression of suppressor genes

Plant-based Active Ingredients - Mechanism of Action & Dosage

HUAIER (Trametes robiniophila Murmur.

Phytochemistry & Composition

The main active ingredient is a Proteoglycan (PS-T) from ~40% polysaccharides, 10% amino acids, 6 monosaccharide types, and 18 amino acids. Huaier is a state-approved TCM preparation in China (Drug Approval Number: Z20000109).

Mechanisms of Action in Detail

  • Mitochondrial apoptosis pathway
    Huaier extract induces apoptosis in breast cancer cells via the mitochondrial pathway: downregulation of Bcl-2 and upregulation of BAX lead to reduction of mitochondrial membrane potential and activation of caspase-3. PubMed
  • EGFR Inhibition (NSCLC)
    In studies of non-small cell lung cancer, Huaier was shown to attenuate EGFR phosphorylation. Molecular docking, kinase activity assays, and cellular thermal shift assays confirmed EGFR as a direct Huaier target receptor, regulating proliferation and apoptosis. PubMed
  • Anti-VEGF / Antiangiogenesis
    Huaier extract dose-dependently inhibits proliferation, motility, and tubule formation of human umbilical vein endothelial cells (HUVECs) in vitro. Western blot analyses showed dose-dependent reduction of phospho-ERK, p65 (NF-κB), JNK, STAT3, and VEGF expression. Angiogenesis was suppressed ex vivo in the chorioallantoic membrane model and rat aortic ring assay. PubMed
  • Immunomodulation - NK cells & T lymphocytes
    A meta-analysis of 29 RCTs with a total of 2,206 cancer patients (hepatocellular, breast, gastric, colorectal, lung, and nasopharyngeal carcinoma) showed that Huaier in combination with conventional therapy significantly improved CD3+, CD4+, NK cell parameters, and immunoglobulins. PubMed Central
  • Wnt/β-Catenin & Cancer Stem Cells
    Comprehensive reviews show that Huaier inhibits tumor cell proliferation, induces apoptosis, suppresses metastasis, and regulates cancer stem cells and immune function. The primary bioactive components include polysaccharides, proteins, ketones, and alkaloids. PubMed
  • Angiogenesis via let-7d-5p/NAP1L1 Axis (Lung Cancer)
    Huaier inhibits angiogenesis and tumor growth in lung cancer by strengthening let-7d-5p and inhibiting NAP1L1. Let-7d-5p is reduced in lung cancer tissue, while NAP1L1 is increased; Huaier restores this balance in vitro and in vivo. PubMed

Clinical evidence

In a prospective study with over 1,000 patients, Huaier granules were proven to lead to prolonged recurrence-free survival (RFS) and overall survival (OS) as adjuvant therapy after hepatectomy in HCC patients. Another study showed significantly prolonged recurrence duration in liver cancer patients compared to TACE monotherapy. Taylor & Francis Online

Study Links

Dosage after therapy phase

phaseRecommendationRemark
Neo-adjuvant20g/day Granules (Study Dose)Strengthen immune status before surgery/chemotherapy
Adjuvant (accompanying)20g/day granules; extract capsules: 3x2g/dayClinically tested standard dosage in RCTs
Palliativ/langfristig20g/day continuously, possibly reduced to maintenance doseLong-term suitability well documented

Reishi (Ganoderma lucidum)

Phytochemistry & Composition

Two main active ingredient groups: Polysaccharides (v.a. beta-glucan, immunomodulatory) and Triterpenes (>150 Ganoderic acid derivatives, antitumoral, antiangiogenic). Optimal extracts: Dual extract (water + ethanol) to capture both fractions.

Mechanisms of Action in Detail

  • PI3K/Akt/mTOR inhibition
    Reishi-treated inflammatory breast cancer cells (SUM-149) showed reduced expression of mTOR downstream effectors as early as 3 hours. 74 out of 84 (88%) PI3K/AKT pathway genes were downregulated, 23%significantly. Reishi affects mTOR on multiple levels, thus showing a broader antitumor effect than single-target compounds. PubMed Central
  • In vivo tumor weight reduction
    SCID-Mäuse mit injiziertem entzündlichem Brustkrebszellen zeigten nach 13-wöchiger Reishi-Behandlung eine Reduktion von Tumorgröße und -gewicht um ~50%. Reishi-behandelte Tumoren wiesen reduzierte Expression von E-Cadherin, mTOR, eIF4G und p70S6K sowie verringerte ERK1/2-Aktivität auf. PubMed
  • Selective Cytotoxicity (Cancer-Specific)
    Reishi selectively inhibits the viability of cancer cells, but does not affect the viability of non-cancerous mammary epithelial cells. Apoptosis induction was consistent with decreased cell viability. PubMed
  • Hematological Malignancies – Apoptosis & Autophagy
    Molecules from Ganoderma lucidum induce mitochondrial damage in acute promyelocytic leukemia cells without cytotoxic effects on normal monocytes. Active lipids from spore powder induce apoptosis via downregulation of P-Akt and upregulation of caspase-3, -8, and -9. PubMed Central
  • TLR-mediated immune activation (β-glucans)
    β-Glucans bind to Toll-like receptors (TLR2/4/6) on macrophages and dendritic cells → NF-κB activation in immune cells (not in tumor cells) → IL-12, TNF-α production → Th1 immune response → NK cell activation

Study Links

Dosage after therapy phase

phaseRecommendationForm
Neo-adjuvant1,500–2,000 mg/dayDual Extract (Triterpenes >4%, Polysaccharides >10%)
Adjuvant (accompanying)2,000–3,000 mg/dayDual extract; higher dose sensible for immunosuppression due to chemotherapy
Palliativ/langfristig1,500–3,000 mg/day as continuous prophylaxisGood long-term tolerability documented

CurcuminTurmeric)

Phytochemistry & Bioavailability Issues

Curcumin is a polyphenol (diarylheptanoid). Critical Problem: Natives curcumin has a bioavailability of <1%% due to poor water solubility, rapid hepatic glucuronidation, and sulfation. This renders standard curcumin preparations largely ineffective for systemic effects.

Bioavailability-enhancing formulations (validated): Sesquiterpenoid combinations (45% Ar-turmerone) or phospholipid complexation (~40% soy lecithin) and nanoparticulate formulations significantly increase plasma peak concentration (Cmax), area under the curve (AUC0-24h), and half-life (T1/2), which signifies prolonged pharmacological effect. PubMed Central

Piperine synergy The combination of curcumin with piperine, an active ingredient in black pepper, increases bioavailability by 2,000%%. Further improvement possibilities include phospholipid complexes, liposomes, and nanoparticles. PubMed Central

Mechanisms of Action in Detail

  • Multitarget Oncology – Signaling Pathway Overview
    Curcumin targets diverse biological processes of oncogenesis. It regulates fundamental dynamics such as cell growth, programmed cell death, angiogenesis, and metastasis by targeting multiple signaling pathways including Wnt/β-catenin, PI3K/Akt/mTOR, JAK/STAT3, MAPK, NF-κB, and Notch. MDPI
  • Apoptosis & Cell Cycle Arrest (Prostate Carcinoma, Systematic Review)
    Curcumin modulated key pathways including PI3K/Akt/mTOR (8 studies), NF-κB (7), AR signaling (6), and apoptosis-related regulators (13). Therapeutic effects included apoptosis, necroptosis, cell cycle arrest, and suppression of migration and angiogenesis. Nanoformulations such as Theracurmin® and PLGA-curcumin demonstrated improved bioavailability and tumor-targeted drug delivery. PubMed Central
  • Ferroptosis induction (newer mechanism)
    Curcumin regulates ferroptosis through interaction with multiple pathways. It promotes ferroptosis in colon carcinomas by interrupting the PI3K/mTOR pathway. Ferroptosis is characterized by intracellular iron accumulation, lipid peroxidation, and GSH depletion. MDPI
  • HDAC Inhibition & Epigenetics
    Curcumin inhibits HDAC1, HDAC3, DNMT1 → Reactivation of silenced tumor suppressor genes → p16, p21 re-expression
  • chemosensitization
    In gastric cancer xenografts, curcumin combined with 5-FU and oxaliplatin significantly inhibited tumor growth through synergistic induction of apoptosis. Tobacco smoke-induced ERK1/2, JNK, p38 activation, as well as increased mesenchymal markers, were reversed by curcumin treatment. MDPI

Clinical Evidence (Systematic Reviews)

A systematic review of 34 RCTs and 2,580 patients showed that curcumin was used as a complementary treatment during cancer therapy, primarily in head and neck cancers, breast, prostate, and colorectal cancers, with effects on inflammatory markers, quality of life, and therapy-related side effects. NF-κB and STAT3, frequently overexpressed in head and neck tumor cells, were modulated. Springer

Study Links

Dosage after therapy phase

phaseRecommendationFormulation
Neo-adjuvant1,000–2,000 mg/dayHighly Bioavailable (BCM-95, Meriva, NovaSOL, Theracurmin)
Adjuvant (accompanying)2,000–4,000 mg/dayNote the timing: do not take at the same time as taxanes (at least 2–4h apart); take with fat
Palliativ/langfristig1,500–3,000 mg/day maintenance therapyContinuous; regular monitoring for anticoagulation

EGCG (Epigallocatechin gallate)

Phytochemistry

Main polyphenol of green tea (Camellia sinensis), catechin subclass. High concentration in unfermented tea. Bioavailability approx. 10–30% (better than curcumin, but dependent on gut flora and dietary companions).

Mechanisms of Action in Detail

  • 67LR – High-affinity EGCG membrane receptor
    Among identified EGCG direct interactors, the transmembrane receptor 67LR was identified as a high-affinity EGCG receptor. 67LR is a master regulator of numerous pathways that influence cell proliferation or apoptosis, and it also regulates cancer stem cell (CSC) activity. EGCG also directly interacts with Pin1, TGFR-II, and metalloproteinases (mainly MMP2 and MMP9). PubMed
  • DNMT Inhibition – Epigenetic Reactivation
    EGCG, the main polyphenol in green tea, can inhibit DNMT activity and reactivate methylation-silenced genes in cancer cells. EGCG inhibited DNMT activity in a dose-dependent manner with competitive inhibition (Ki = 6.89 µM). In human esophageal carcinoma cells KYSE 510, EGCG (5–50 µM) caused time-dependent reversal of hypermethylation of the genes p16(INK4a), RARβ, MGMT, and hMLH1. PubMed
  • Telomerase Inhibition (hTERT)
    In MCF-7 breast cancer cells and HL60 leukemia cells, EGCG reduced cellular proliferation and induced apoptosis. Epigenetic and genetic mechanisms contribute to telomerase inhibition: EGCG inhibits DNMT1 methylation capacity, leading to hypomethylation of the hTERT promoter, thereby enabling binding of the Rb/E2F-1/HDAC1 repressor complex → reduced hTERT transcription. PubMed
  • Tumor Microenvironment – Metabolic Reprogramming
    EGCG regulates the tumor microenvironment and metabolic reprogramming: it inhibits tumor stromal cell activation, adhesion, proliferation, migration, inflammatory cytokine and chemokine secretion, and angiogenesis. Molecular mechanisms involve the inhibition of Rho/ROCK, ECM/Integrin, RTKs/PI3K/Akt/mTOR, TGF-β/Smad, MAPK/ERK, JAK/STAT3, NF-κB, 67LR/TLR4, and HIF-1α signaling pathways. EGCG suppresses glucose uptake, aerobic glycolysis, glutamine metabolism, fatty acid anabolism, and nucleotide synthesis. PubMed
  • Glioblastoma – Telomere Shortening
    Chronic treatment of U251 glioblastoma cells with physiologically realistic EGCG concentrations: inhibition of telomerase activity led to telomere shortening, senescence, and telomere dysfunction after 98 days. DNA damage was also observed via increased γ-H2AX phosphorylation and micronuclei even before telomere shortening. PubMed

Study Links

Dosage after therapy phase

phaseRecommendationRemark
Neo-adjuvant400–600 mg EGCG/Tag (≥98%%-standardized)Sober or with a light meal
Adjuvant (accompanying)600–800 mg/dayNot with Bortezomib (Antagonism); minimum 4h separation from other substances
Palliative400–600 mg/day; if necessary, green tea extract 2–3 cups additionallyHeavy metal tested preparations; may cause stomach irritation

Barbary

Phytochemistry

Isoquinoline alkaloid from various plants (barberry, goldenseal root, Coptis chinensis). Molecular structure similar to metformin in its AMPK activation ability, but differs in exact binding kinetics.

Mechanisms of Action in Detail

  • Warburg effect reversal via Akt/mTOR/GLUT1
    Berberine exhibits antineoplastic effects by reversing the Warburg effect through downregulation of the Akt/mTOR/GLUT1 signaling pathway. Berberine inhibited glucose uptake and reduced transcription of GLUT1, LDHA, and HK2 in colon cancer cells via HIF-1α protein synthesis inhibition by mTOR suppression. PubMed Central
  • AMPK Activation & mTOR Inhibition (Colorectal Cancer)
    Berberin aktiviert AMPK, das über AMPK-abhängige mTOR-Inhibition die Dickdarmepithelproliferation und -tumorigenese unterdrückt. 4E-Bindungsprotein-1 und p70 ribosomale S6-Kinasen — Downstream-Targets von mTOR — wurden durch Berberin herunterreguliert. Berberin supprimierte Tumorigenese im AOM/DSS-Mausmodell: 60% Reduktion der Tumorzahl, 100% Reduktion von Tumoren >4mm. PubMed
  • Multiple signal pathway intervention
    Berberine inhibits cancer cell proliferation, promotes apoptosis and autophagy in cancer cells, and prevents metastasis and angiogenesis. The mechanism involves multiple cell kinases and signaling pathways: activation of AMPK and FOXO3a, ROS accumulation, and inhibition of PI3K/AKT, mTOR, and NF-κB. Most mechanisms converge on the regulation of the AMPK/PI3K-AKT balance. PubMed
  • Gastrointestinal Carcinomas – Clinical Data
    In esophageal carcinoma cell lines (KYSE-70 and SKGT4), berberine inhibited cell survival and proliferation by suppressing Akt and mTOR phosphorylation and promoting AMPK phosphorylation. Increased RAD51 expression in esophageal carcinoma cells was associated with radioresistance; berberine significantly suppressed RAD51 expression and attenuated radioresistance. Wiley Online Library
  • Metformin parallelism
    Berberine activates AMPK via a metformin-like mechanism. Both substances can attenuate EMT (Epithelial-Mesenchymal Transition). The LKB1/AMPK/mTORC1 pathway runs in parallel: berberine increases AMP levels, promoting AMPK activation via LKB1 phosphorylation, which leads to TSC1/TSC2 complex activation and subsequent mTORC1 inhibition. Oncotarget

Study Links

Dosage after therapy phase

phaseRecommendationRemark
Neo-adjuvant500 mg twice a day with mealsCheck for CYP3A4 interactions
Adjuvant (accompanying)500 mg 3 times/day with mealsDo not combine with CYP3A4 substrates without medical clearance
Palliative500 mg 2-3 times/day; well tolerated long-termGood for the microbiome; butyrate production ↑

Sulforaphane (SFN)

Phytochemistry & Biosynthesis

Isothiocyanate, formed by enzymatic hydrolysis of Glucoraphanin through Myrosinase When chewing cruciferous vegetables. Important: Myrosinase is heat-sensitive — cooked broccoli contains hardly any active sulforaphane. Broccoli sprouts contain 10–100× more glucoraphanin than mature broccoli.

Critical Gut flora composition and genetic GST polymorphisms significantly influence individual sulforaphane bioavailability.

Mechanisms of Action in Detail

  • Nrf2/Keap1 Activation – Phase II Enzymes
    Sulforaphane, produced by hydrolytic conversion of glucoraphanin after consumption of cruciferous vegetables, possesses far-reaching health-promoting properties. Sulforaphane disrupts the Nrf2-Keap1 complex through degradative loss of Keap1 via conformational changes. Specific Keap1 modifications liberate Nrf2, promoting its nuclear translocation and activation. Nrf2 heterodimerizes with small Maf transcription factors and binds to Antioxidant/Electrophile Response Elements (ARE/EpRE) in promoter regions → upregulation of phase II antioxidant enzymes (GST, NQO1, HMOX1). PubMed
  • HDAC Inhibition — p16 Reactivation
    The tumor suppressor p16(INK4a) is suppressed in colon carcinomas by increased HDAC activity. Sulforaphane reduces HDAC3 protein expression and activity in mouse tumors. Humans administered broccoli sprout extract (200 µmol SFN equivalents) showed increased p16 expression that was inversely associated with HDAC3 in circulating peripheral blood monocytes and biopsy samples. PubMed
  • Selective Cancer Stem Cell (CSC) Toxicity
    Sulforaphane can specifically target a cancer cell population with stem cell-like properties (cancer stem cells, CSCs). SFN can inhibit aberrantly activated embryonic pathways in CSCs: Sonic Hedgehog (SHH), Wnt/β-Catenin, Cripto-1, and Notch. SFN downregulates CSC-related genes such as CD133, CD44, ALDH, c-Myc, Nanog, Oct-4, hTERT, and MMP2. PubMed Central
  • Chemosensitization (Doxorubicin, Gemcitabine)
    In an orthotopic breast cancer model, sulforaphane enhanced the cytotoxic effects of doxorubicin, inhibited tumor growth, and exerted cardioprotective effects by reducing cardiac oxidative stress. SFN plus doxorubicin showed a significant reduction in tumor volume, increased cytotoxic CD8+ T cells, and decreased myeloid-derived suppressor cells (MDSCs). PubMed Central
  • Multiscale Perspective (2025)
    Sulforaphane has evolved from a dietary antioxidant to a sophisticated multi-target oncological agent. Beyond the well-established roles of Nrf2 activation and HDAC inhibition, newer mechanisms of action include ferroptosis induction, targeting therapy-resistant CSCs, and remodeling the tumor immune microenvironment. Gut microbiota composition and GST polymorphisms significantly modulate bioavailability and efficacy, suggesting a precision nutrition paradigm for personalized application. PubMed

Study Links

Dosage after therapy phase

phaseRecommendationForm
Neo-adjuvant20–40 mg Sulforaphane/TagMyrosinase-active sprout concentrate; OR ~70g fresh broccoli sprouts
Adjuvant (accompanying)40 mg/dayStandardized extract with active myrosinase system; not heated
Palliative20–40 mg/day continuouslyCombination with fresh cruciferous vegetables (arugula, radish)

Omega-3 Fatty Acids (EPA/DHA)

Phytochemistry & Active Ingredient Identity

Eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3). Main sources: fatty marine fish, algae oil (vegan). Alpha-linolenic acid (ALA) from plant sources is only inefficiently converted to EPA/DHA (<5%).

Mechanisms of Action in Detail

  • Membrane Modification & Receptor Signaling
    EPA and DHA are rapidly incorporated into cell membranes and lipid rafts. Their integration can influence membrane-associated signaling proteins such as Ras, Akt, and Her-2/neu. Furthermore, due to their high sensitivity to oxidation, it has been proposed that n-3 PUFAs can cause irreversible tumor cell damage by increasing lipid peroxidation. PubMed
  • Arachidonic acid cascade inhibition
    EPA and DHA competitively substitute arachidonic acid (AA) in membranes. The membrane lipid composition is shifted from omega-6-PUFA-rich to omega-3-PUFA-rich. This increases the production of less inflammatory omega-3 mediators (thromboxane A3, prostacyclin I3) compared to highly inflammatory eicosanoids (PGE2, LTB4). Systematic reviews showed reductions in thromboxane B2 and leukotriene B4. PubMed Central
  • CSC-Targeting
    EPA and DHA (10–70 µM) separately induced apoptosis in cancer stem cell-like cells of the SW620 colon carcinoma cell line; the effect was significantly enhanced when applied simultaneously. n-3 PUFAs also act against therapy-resistant CSCs, which are responsible for tumor recurrence and metastasis. PubMed Central
  • Synergism with chemotherapy
    Several studies have analyzed the synergy between EPA/DHA and standard CRC chemotherapy. Vasudevan et al. demonstrated a synergistic anti-cancer effect between EPA and a combination of 5-fluorouracil and oxaliplatin in vitro and in vivo against HT29 and HCT116 CRC models. EPA and DHA were also able to reduce doxorubicin resistance by inhibiting P-glycoprotein efflux pump expression in resistant HT29 cells. PubMed Central
  • Anti-PD-1 Synergism (Immunotherapy)
    A study report indicated potential synergistic therapeutic benefits of combining anti-PD-1 treatment with omega-3 PUFA supplementation in squamous cell carcinoma of the esophagus. This represents a promising direction for further research. PubMed
  • Clinical Meta-Analysis (Chemotherapy Support)
    Systematic Review of 10 high-quality RCTs: The combination of omega-3 fatty acid supplements with conventional chemotherapy was beneficial in studies of high methodologic quality. Daily EPA/DHA doses ranged from 600 mg to 3.6 g. None of the studies showed worse outcomes for the supplementation group. Preservation of body composition was the most pronounced benefit. PubMed

Study Links

Dosage after therapy phase

phaseRecommendationQuality
Neo-adjuvant2–3 g EPA+DHA/TagIFOS 5-Star Certified Fish Oil or Algal Oil
Adjuvant (accompanying)3–4 g EPA+DHA/TagStart >6 months after chemotherapy completion due to possible GI intolerance; EPA:DHA ratio ~2:1 preferred
Palliative (long-term/cachexia prevention)2–4 g/day continuouslyCachexia prophylaxis well documented; daily with a high-fat meal

Vitamin D3 + K2

Physiology & Activation

Vitamin D3 (Cholecalciferol) → Liver: 25-hydroxylation to 25(OH)D → Kidney: 1α-hydroxylation to active Calcitriol (1,25(OH)₂D₃). Calcitriol binds VDR (Vitamin D Receptor), a nuclear steroid receptor → Heterodimer with RXR → Binding to VDREs (Vitamin D Response Elements) → Regulation of ~3% of the human genome (~200+ genes).

Mechanisms of Action in Detail

  • VDR-genomic signaling cascade – tumor suppression
    Vitamin D3 acts as a direct regulator of the epigenome and transcriptome in various tissues and cell types, including malignant tumor cells. Significant effects on immune cell proliferation, differentiation, and apoptosis also have implications for cancer cells. Calcitriol inhibits cell proliferation and induces apoptosis in vitro. Various tissues, including colorectal epithelial cells, express VDR and possess the enzymatic machinery for converting circulating 25(OH)D into active metabolites → induction of cell differentiation and inhibition of proliferation, invasiveness, angiogenesis, and metastatic potential. ScienceDirect
  • Wnt/β-Catenin Inhibition (Colorectal Carcinoma)
    1,25(OH)₂D induces colon cancer cell differentiation by repressing the WNT/β-catenin signaling pathway through multiple mechanisms: increased nuclear export and decreased β-catenin availability, enhanced expression of the WNT/β-catenin inhibitor DKK-1, and suppression of WNT/β-catenin downstream targets c-Myc and cyclin D. Frontiers
  • Clinical Evidence – Cancer Mortality Reduction
    Systematic review and individual patient data meta-analysis of 14 RCTs with a total of 104,727 participants and 2,015 cancer deaths: In a daily dosing schedule, the vitamin D3 group showed 12%lower cancer mortality compared to the placebo group (RR 0.88 [95% CI 0.78–0.98]), whereas no mortality benefit was observed with bolus dosing schedules. PubMed Central
  • Chemosensitization & VDR as Biomarkers
    Bei Brustkrebspatienten unter neoadjuvanter Chemotherapie waren adäquate Vitamin-D-Ausgangsspiegel mit 22% Reduktion des Risikos einer Non-Response und 35% Reduktion des Progressionsrisikos assoziiert. Calcitriol-Vorbehandlung von MCF-7-Brustkrebszellen reduzierte Expression und Aktivität von Cu/Zn-Superoxiddismutase (SOD), was erhöhte Sensitivität gegenüber ROS-Species durch Anthrazykline nahelegt. MDPI
  • Gut-Microbiome-Immunotherapy Axis (Science, 2024)
    Vitamin D acts on intestinal epithelial cells → alters gut flora towards Bacteroides fragilis → enhanced anti-tumor immunity; increased response to checkpoint inhibitors (PD-1/PD-L1) in lung cancer patients correlates with vitamin D status.
  • Vitamin K2 (MK-7)
    Synergistic: K2 activates Matrix Gla Protein → prevents calcitriol-induced soft tissue calcification; direct effect on osteocalcin; in vitro anti-proliferative in myeloma cells.

Study Links

Dosage after therapy phase

phaseRecommendationMonitoring
Preventive/NeoadjuvantSerum determination (25-OH-D); Target value: 40–60 ng/ml; typically 2,000–5,000 IU D3/day + 100–200 µg MK-7/day25-OH-D every 3 months
Adjuvant (accompanying)5,000 IU/day (possibly higher in case of deficiency); daily dosage; + 200 mcg MK-7Monitor serum calcium; daily administration more effective than bolus
Palliative3,000–5,000 IU/day permanentlyEven with hypercalcemia risk: monitor serum levels

Melatonin (oncologically high-dose)

Physiology

Hormone of the pineal gland, synthesized from tryptophan → serotonin → melatonin. Binds to MT1/MT2 G-protein-coupled receptors. Physiological serum concentrations: 100–200 pg/ml. Oncological dosages (20–40 mg/night) are 1,000 times higher.

Mechanisms of Action in Detail

  • VEGF/HIF-1α Inhibition (Anti-angiogenesis)
    Melatonin inhibited the hypoxia-induced increase in phospho-STAT3, CBP/p300, and HIF-1α and inhibited their physical interaction, suggesting that melatonin exerts its anti-angiogenic effect by interfering with VEGF transcriptional activation via HIF-1α and STAT3. PubMed Central

    Many studies link melatonin to the inhibition of VEGF and inactivation of HIF-1α, meaning that melatonin neutralizes pro-angiogenic effects and potentiates the anti-angiogenic effects of chemotherapy or radiation, thereby increasing their anti-tumor efficacy. PubMed Central
  • Chemotherapy Potentiation – Clinical Meta-Analysis
    Melatonin may benefit cancer patients undergoing chemotherapy, radiotherapy, supportive, or palliative therapy by improving survival rates and reducing the toxic side effects of chemotherapy. PubMed
  • Sorafenib Synergy (HCC) & HIF-1α
    In hepatocellular carcinoma (Hep3B cells), melatonin enhanced the cytotoxic effects of sorafenib and helped overcome resistance mechanisms mediated by hypoxia. At pharmacological concentrations (2 mM), melatonin potentiated sorafenib effects under hypoxia; HIF-1α was downregulated by melatonin. PubMed Central
  • DNA protection during chemotherapy (RCT)
    MIRCIT Study (randomized, double-blind, placebo-controlled): Patients with advanced NSCLC received 10 mg or 20 mg of melatonin or placebo. DNA damage marker 8-oxodG was significantly elevated in the placebo group and associated with lower survival (r²=−0.656, p=0.02), suggesting a protective effect of melatonin on healthy cells. Anticancer Research
  • Multiple Mechanism — Full Overview: Mechanisms of Melatonin's Anti-Cancer Effect: Inhibition of Initiation, Progression, and Metastasis via Multiple Signaling Cascades. Synergistic Actions with Radio- or Chemotherapies (left in the diagram) and Resensitization of Therapy-Resistant Cancers by Melatonin. PubMed

Study Links

Dosage after therapy phase

phaseRecommendationRemark
Neo-adjuvant10–20 mg/night (1–2 hours before sleep)Improve sleep quality; preemptive immune priming before surgery
Adjuvant (accompanies chemo/radiation)20 mg/nightExclusively under oncological supervision; data for immunotherapy (PD-1/PD-L1) still unclear
Palliativ/langfristig20–40 mg/nightOff-label, with medical supervision only; normalize circadian rhythm

Breakdown by therapy phase

Neoadjuvant Phase

(Before operation / before first systemic therapy)

Goals Strengthen the immune system, make tumor biology unfavorable, prepare the body for demanding therapy, improve surgical outcome.

Priority measures

MeasureReasonTiming
Vitamin D3 OptimizationCorrecting deficiencies before chemotherapy (increased chemosensitivity); improving immune response4–8 weeks before the start of therapy; determine levels
Omega-3 (EPA/DHA, 2g/Day)Pre-treat tumor microenvironment; PGE2↓; improve immunopolarizationAt least 4–6 weeks' lead time required for membrane integration
Reishi (1,500 mg)NK cell priming; Improve immune status; mTOR inhibitionContinuously from diagnosis
Huaier (20g/day)Immunomodulation; adjuvant effect provenFrom diagnosis; in China adjuvant after surgery standard
Sulforaphane (20–40 mg)Phase II enzyme-induced; DNA protection; HDAC preparationDaily via sprouts or extract
Intermittent Fasting (16:8)Insulin sensitization; AMPK; lowering mTOR basal levelsOnly if there is no cachexia/malnutrition

Adjuvant Phase

(Supportive care during chemotherapy / radiation therapy / surgery)

Goals Increase therapy efficacy, mitigate side effects, slow resistance development, support the immune system.

Special caution due to interactions (see Section 9)

SubstanceBenefits during chemoImportant restriction
Omega-3 (3–4 g/day)Chemosensitization (5-FU, oxaliplatin, taxanes); cachexia prevention; anti-CRSMonitor GI tolerance; start as early as possible before chemo starts
Vitamin D3 (5,000 IU)Increased chemosensitivity; decreased paclitaxel-induced neuropathy; decreased anthracycline cardiotoxicityMonitor calcium
Melatonin (20 mg/night)DNA protection for healthy cells; quality of life ↑; potentiates cisplatin, doxorubicin; VEGF ↓Not simultaneously with immunotherapy (data unclear)
Huaier (20g/day)Restore immune function after chemo; prolong OS/RFS (RCT-proven)Well tolerated; no known interactions with standard chemotherapy drugs
Curcumin (highly bioavailable, 2g/day)NF-κB↓; Chemosensitization; Inflammation↓Not concurrently with taxanes (Timing!); not with bortezomib
Berberine (500 mg 3×/Day)AMPK; Warburg Inhibition; Gut FloraCheck CYP3A4; distance to chemotherapy
SulforaphaneHDAC; Phase-II-Enzyme; KrebsstammzellenDuring radiation therapy consultation (Antioxidant activity could influence radiotherapy effect)
ReishiImmune reconstitution; NK cells; TLR activationNo known significant interactions

Nutritional adjuvant

  • Moderate-to-high protein (cachexia prevention) - plant-focused but not low-protein
  • Low-Glycemic (GI <50), no sugar — Stabilize insulin levels
  • High fiber density (30–40 g/day) — butyrate microbiome epigenetics
  • Mediterranean Diet as a Guiding Principle

Palliative and long-term phase

(Post-Therapy Maintenance / Metastasis / Relapse Prevention)

Goals Relapse prevention, permanently activate immune surveillance, keep the metabolic tumor microenvironment unfavorable, maintain quality of life.

SubstanceLong-term dosingPrimary goal
Vitamin D3 + K23,000–5,000 IU D3 + 200 µg MK-7 permanentlyVDR Signaling; Immunesurveillance; 12% Mortality Reduction (RCT-proven)
Omega-32–3 g/day long-termChronic inflammation ↓; Recurrence prevention; Microbiome
Reishi1,500–2,000 mg/dayImmunomodulation; Long-term mTOR inhibition
Huaier20g/day granules; maintenance doseRFS↑; OS↑ in clinical trials (HCC, Breast, Colorectal)
Barbary500 mg twice a dayPrevent Metabolic Syndrome; Insulin Sensitivity; Microbiome
Sulforaphane20–40 mg/day or 5× sprouts/weekCSC-Surveillance; HDAC-continuous; Chemoprevention recurrence
EGCG400–600 mg/dayTelomerase; DNMT; Epigenetic maintenance
Melatonin20 mg/night or reduced to 10 mgCircadian Restoration; VEGF↓; Immune surveillance at night
Curcumin1,500–2,000 mg highly bioavailableNF-κB chronically downregulated; inflammation prevention

Palliative exercise

  • Aerobic activity (150 min/week, moderate intensity): NK cell mobilization, irisin release (inhibits tumor growth), immune microenvironment
  • Strength Training: IGF-1 Normalization; Sarcopenia Prevention; Cachexia Protection

Interactions & Contraindications

SubstanceInteracts withMechanismRecommendation
CurcuminTaxanes (Paclitaxel, Docetaxel)P-glycoprotein induction possible → altered taxane plasma levelsAt least 4–6 hours apart; after chemo session
CurcuminBortezomib (Velcade)In-vitro antagonism describedAvoid combination
CurcuminWarfarin / AnticoagulantsCOX inhibition, platelet functionClosely monitor INR
EGCGBortezomibDirect complex formation → Bortezomib loss of efficacyCombination contraindicated
BarbaryCYP3A4 Substrate (Imatinib, many chemotherapeutics)CYP3A4 inhibition → increased plasma levelsInteraction check mandatory
BarbaryMetforminAdditive AMPK activation → Risk of hypoglycemiaDose adjustment; Blood glucose monitoring
Omega-3 high dosageAnticoagulantsPlatelet aggregation inhibitionMonitor INR; Above 3g EPA+DHA
MelatoninPD-1/PD-L1 immunotherapyInteraction with immune activation; data unclearConsulting oncologists
MelatoninChemotherapy TimingCircadian-dependent effect enhancementAdminister in the evening/at night
High-dose antioxidantsRadiotherapyPotential mitigation of ROS-induced tumor cell death by radiationPause Sulforaphane, EGCG, and Curcumin during radiation or keep a 4–6 hour interval
High-dose Vitamin DHypercalcemiaExcess → Calcitriol → Calcium ReleaseRegularly monitor serum calcium and phosphate
ReishiImmunosuppressantsImmunostimulation can influence the effect of cyclosporineAfter transplant: Caution

Quality Criteria for Preparations

Since direct links to products cannot be linked (quality and availability change), here are the validated quality criteria:

Mushroom Extracts (Huaier, Reishi):

  • Dual Extract (Hot Water + Ethanol): Captures both β-glucans (water-soluble) and triterpenes (alcohol-soluble)
  • Zertifizierter β-Glucan-Gehalt >10% auf Etikett (nicht Polysaccharide gesamt)
  • No mycelium-on-grain products (mainly contain starch, little active ingredient)
  • Heavy metal and mycotoxin tests (CoA available)

Curcumin:

  • Patented formulations: Meriva® (phospholipid), Longvida® (optimized lipid particles), BCM-95® (sesquiterpenoids), NovaSOL® / Cureit® (micellar)
  • Bioavailability studies of the formulation available

Omega-3

  • IFOS (International Fish Oil Standards) 5-Star Certification
  • Total EPA+DHA as stated on label (not just total fish oil amount)
  • Triglyceride form preferred (better absorbed than ethyl esters)

EGCG:

  • Standardization to ≥98%% EGCG
  • Tested for heavy metals (tea can accumulate lead)
  • Dry extract (not an aqueous infusion for dosage accuracy)

Sulforaphane

  • Myrosinase-active formulations (TrueBroc® = Broccoli sprouts + myrosinase; or fresh sprouts)
  • Glucoraphanin alone is biologically inactive – the myrosinase system is essential

Summary - Recommended combination by logical sense

Neoadjuvant (Priority): Vitamin D3 Optimization + Omega-3 Loading + Reishi/Huaier + Sulforaphane + Dietary Change

Adjuvant accompanying: All of the above + Melatonin + phase-appropriate curcumin integration (timing!) + berberine (if no CYP conflict)

Palliative/Long-term Care Basis-Stack (D3+K2, Omega-3, Reishi, Huaier, Berberine, SFN, EGCG, Melatonin) + continuous movement + low-GI diet permanently

Sources of supply

When selecting suppliers, it is absolutely essential to note that you should not rely on information in brochures or product descriptions, but rather on analyses from independent laboratories! If product pages lack links to analysis data, you should contact the sales department/manufacturer and request that they be provided.

Below is a list (as of April 2026) of recommended sources:

1. Huaier – Qualitätsführend mit vollständiger Laboranalytik

Nutrimentas (Muntendorf e.K.) – 32% Polysaccharide + complete CoA

The product is a standardized extract powder from the fruiting body of Trametes robiniophila Murrill. The following parameters were analytically determined and documented for the current batch: β-glucan content using suitable analytical methods, batch-specific amino acid profile, and environmental analysis by GBA (Gesellschaft für Bioanalytik) including heavy metals, pesticide residues, and microbiological parameters. Ergosterol as a quality indicator for the raw material is also documented. Physical properties: powder form, water-soluble up to 70°C, hygroscopic.

Direct links to the Certificates of Analysis on the product page:

Product Page (350g, €129): https://nutrimentas-shop.de/products/vitalpilz-huaier-trametes-robiniophila-fur-wissenschaftliche-zwecke

Note: The product is declared on the page as „for research and analysis purposes“ – not a food, not a dietary supplement – as this is the legally correct labeling in Germany for substances that are not approved as pharmaceuticals.
Active ingredient content and quality correspond to the clinical study preparation. 32%polysaccharides surpass the pharmacy product (only 30%) in quality.

Dosage: Dissolve 3x 20g/day in warm water (up to 70°C), as the active ingredients only develop their effect when heated!

Notice:
Different manufacturing processes are used, which may influence the dosage, e.g., 1x20g instead of 3x20g. Therefore, please read the package insert!

Es gibt vermeintlich „günstige“ Anbieter von Huaier-Granulat. Unterschied zwischen dem „teuren“ und „günstigen“ Produkt ist, dass das teure aus dem Fruchtkörper des Huaier-Pilzes gewonen wird, während das günstige aus dem Myzel auf z.B. Getreide hergestellt wird, dessen Wirkstoffgehalt z.T. nur ein Zehntel beträgt und 90% an, bei der Festkörperfermentation, unverdautem Füllstoff enthält.

Hingegen sind bei Flüssigfermentation, bei dem Myzel in nährstoffreichen Flüssigmedien kultiviert wird, wiederum Wirkstoffe enthalten, die nicht aus dem Fruchtkörper gewonnen werden können.

Als „Fruchtkörper“ bezeichnet man den Pilz, wie er optisch wahrgenommen wird, als „Myzel“ das Innere des Pilzes.

2. Reishi – Dual-Extrakt mit verifizierten Polysaccharid-Gehalten

Green Naturals (Germany) — 40% Polysaccharide, lab tested

Jede Tagesdosis enthält 2.100 mg Reishi-Extrakt, davon 40% bioaktive Polysaccharide. Herstellung in Deutschland unter strengen Qualitätskontrollen. Frei von Zusatzstoffen, glutenfrei, laktosefrei, ohne Magnesiumstearat. Kapseln können geöffnet werden.

Product page (directly from the manufacturer): https://www.green-naturals.de/products/reishi

Why this provider? 40% polysaccharide is significantly higher than the typical 10–13% on the market. Capsules can be opened and dissolved in liquid—important for the ileostomy phase.

Alternative: smaints.de — Organic dual extract, European cultivation, independent laboratory testing

Bio Reishi Dual-Extract Capsules from European Cultivation, Independently Lab-Tested, Vegan, Filler-Free.
The dual-extraction method captures both β-glucans (water-soluble) and triterpenes (alcohol-soluble). Saint

3. Curcumin – Meriva® Phytosome, clearly declared curcumin content

Doctor's Best Curcumin Phytosome (Meriva®) — via ergomax.de

Ingredients per daily dose (2 capsules): Curcumin Phytosome® (Meriva®): 1,000 mg phospholipid-curcuminoid complex, at least 180 mg pure curcumin and other curcuminoids. Patented phytosome technology with phosphatidylcholine. Vegan capsule shell. No soy, gluten, or GMO ingredients.

Product page https://www.ergomax.de/products/doctors-best-curcumin-phytosom-meriva

Dosage for this case: 4 capsules/day = 360 mg pure curcumin as phytosome (equivalent to approx. 2,700 mg native curcumin according to bioavailability studies). With a fatty meal.
At least 4–6 hours between chemotherapy infusions.

4. Berberine – 97% HCl, water/ethanol extraction

sunday.de – Premium Berberine Extract 500mg

Berberin aus indischem Premium Berberitzen-Wurzelextrakt. 97% Berberin-HCl. Hochkonzentriert. Extraktion ausschließlich mit Wasser und Ethanol (Lebensmittelqualität), ohne chemische Lösungsmittel. 100% vegan.

Product page (90 capsules): https://www.sunday.de/berberin-kapseln.html

Value Set (2x90 capsules, cheaper): https://www.sunday.de/berberin-hcl-extrakt-kapseln-set.html

Dosage: 500 mg 2–3 times daily with meals. CYP3A4 interaction check mandatory before starting chemotherapy.

5. Sulforaphane – Myrosinase-Activated

Life Force Pure Sulforaphane Formula — Glucoraphanin + Active Myrosinase

Contains 45 mg glucoraphanin and 4.8% active myrosinase per capsule. Myrosinase largely retains its conversion activity even after gastric passage. Vitamin C as a cofactor optimizes enzyme activity. No gastric-resistant coating. Very sensitive, store unopened in original packaging, do not pre-portion.

Product page https://www.lebenskraftpur.de/products/sulforaphan-kapseln-formula

Alternative: Scheunengut® via Shop-Apotheke — 30:1 Extract, Active Myrosinase, German Raw Material

Broccoli extract 30:1 from German raw material, 10% sulforaphane, with active myrosinase, vegan capsule shell.
Clear mg specification: minimum 50 mg sulforaphane per capsule. Shop Pharmacy

Product Page (Shop-Apotheke - Licensed German Pharmacy): https://www.shop-apotheke.com/ernaehrung/upmEWM7PM/scheunengut-brokkoli-kapseln-brokkoli-30-1-extrakt-aktive-myrosinase-i-10-sulforaphan-i-vegan.htm

Dosage: 1–2 capsules of Scheunengut (50–100 mg sulforaphane) or 2 capsules of Lebenskraftpur daily.
On radiation therapy days: at least 4-hour separation or consult with oncologist.

6. Omega-3 - IFOS Certified, Verified EPA+DHA Content

NORSAN Omega-3 Total (Liquid) — IFOS + GOED + Cologne List®, Triple Certified

NORSAN, in comparison to other market products, is the only one to use a natural, full-spectrum fish oil from whole wild fish instead of a concentrate. Triple independent laboratory analysis: IFOS, GOED, and Kölner Liste®. Fatty acids in their natural triglyceride form.

Precise ingredients of the liquid oil per daily dose (8 ml): Per 8 ml daily dose: 2,000 mg Omega-3 fatty acids, of which EPA 1,120 mg, DHA 536 mg, DPA 128 mg. Additionally, Vitamin D3 800 IU and Vitamin E. Ingredients: Natural fish oil, olive oil, tocopherols, cholecalciferol, natural lemon oil.

Direct product page link: https://norsan.de/

In case of an ileostomy: Prefer liquid oil as it's better absorbed than gelatin capsules. Pre-operative: Stop 7–10 days prior. For oncological dosing (3–4 g EPA+DHA): 1.5–2 tablespoons daily with a fatty meal.

If capsules are preferred: NORSAN Omega-3 Capsules

A daily dose (4 capsules) provides 1,500 mg of omega-3 fatty acids (EPA and DHA), with a total of 1,075 mg EPA+DHA. IFOS 5-star certified. Natural triglyceride form. No unpleasant fishy aftertaste.

Product page https://norsan.de/shop/omega-3-kapseln/

7. Vitamin D3 + K2

Nutrimenta also offers a Vitamin D3/K2 product in its own assortment (Zestonics brand):

Vitamin D3/K2 Drops (1,000 IU/drop, vegan, 1,020 drops): https://nutrimentas-shop.de/products/vitamin-d3-k2-1020-tropfen-vegan-1000-i-e

Dosage: 5 drops = 5,000 IU D3 daily (adjusted according to blood levels). Check serum calcium every 8 weeks.

8. High-dose melatonin

For 20 mg/night (oncological), no pre-packaged dietary supplements are approved in Germany.

Options:

Option A – Pharmacy Prescription: A general practitioner or oncologist can prescribe melatonin 20 mg as a custom-compounded capsule through a compounding pharmacy. This is the safest and best-documented method with pharmaceutically guaranteed purity standards.

Option B – Vitabay (up to 10 mg, 2 capsules each in the evening): https://www.vitabay.net/

Summary Quality Matrix — Verified

SubstanceRecommended ProductActive ingredient contentCertificationDirect link
HuaierNutrimentas MycoPure32% PolysaccharideGBA-Laboratory Analysis, CoA onlinehttps://nutrimentas-shop.de/products/vitalpilz-huaier-trametes-robiniophila-fur-wissenschaftliche-zwecke
ReishiGreen Naturals40% PolysaccharideDE-Production, lab-testedhttps://www.green-naturals.de/products/reishi
CurcuminDoctor's Best Meriva®180 mg Curcumin/2 CapsulesPatented Meriva® Technology (Indena)https://www.ergomax.de/products/doctors-best-curcumin-phytosom-meriva
Barbarysunday.de97% Berberine HClEthanol extraction, no chemicalshttps://www.sunday.de/berberin-kapseln.html
SulforaphaneVitality / Barn Estate45 mg Glucoraphanin + Myrosinase / 50 mg SFNActive myrosinase verifiedhttps://www.lebenskraftpur.de/products/sulforaphan-kapseln-formula
Omega-3NORSAN Total (liquid)1.120 mg EPA + 536 mg DHA/8 mlIFOS + GOED + Cologne List®https://norsan.de/
Vitamin D3+K2Nutrimentas/Zestonics Drops1,000 IU/drop, K2 MK-7Vegan, German productionhttps://nutrimentas-shop.de/products/vitamin-d3-k2-1020-tropfen-vegan-1000-i-e
MelatoninPharmacy compoundingIndividually according to prescriptionPharmaceutical purityAbout General Practitioner/Oncologist

All mentioned measures should be understood as supplementary to conventional medical therapy. The literature links exclusively refer to PubMed, PMC, Springer Nature, Wiley, MDPI, Frontiers, PLOS ONE, and comparable scientific publishers.

Dosage recommendations may require adjustments depending on the current data from lab reports and other circumstances, such as ileostomy, if absorption is impaired, etc., and must therefore always be coordinated individually – also in collaboration with healthcare providers.

Leave a Reply

Your email address will not be published. Required fields are marked *